Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma

Conesa‐Zamora, Pablo; Santaclara, V; Gadea-Niñoles, E.; Ortiz-Reina, Sebastián; Pérez‐Guillermo, Miguel

doi:10.1016/j.humimm.2009.11.012

Cited by 9 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA was extracted from patient buffy coat using the QiaAmp DNA Mini Kit (ref: 51306) and Qiacube automatic extractor by Qiagen (Hilden, Germany). FcGR3A V158F genotyping was performed by nested polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) as described previously 14 in order to selectively amplify the FCGR3A and not FCGR3B gene. Briefly, in the first PCR, 1 μl of DNA was amplified in reaction mixture of 10 μl volume, containing 0.4mM dNTPs, 3 pmol of each primer, 7.5 mM MgCl2, and 1 U Taq DNA polymerase (annealing temperature, 57ºC).…”

Section: Methodsmentioning

confidence: 99%

A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF

Romero-Cara¹,

Torres-Moreno²,

Pedregosa³

et al. 2018

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background. The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). Since receptors for the Fc portion of IgG (FCGRs) are involved in the degradation of IgG complexes, we hypothesised that a polymorphism in FCGR3A (V158F; rs396991) gene could be involved in anti-TNF ADA generation and treatment resistance. Material and Methods. A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured. Results. No significant differences were observed between ADA occurrence or V158F genotype and type of disease or the kind of anti-TNF administrated. Interestingly, VV genotype correlated with patients producing ADA (VV: 37.5% vs. FV: 10.6% or FF: 5%; p=0.004) and was an independent predictor of this event after multivariate analysis. Moreover, VV genotype also correlated with those patients receiving anti-TNF dose intensification (p=0.03). Conclusion. FCGR3A V158F polymorphism seems to be associated with ADA production against mAbs and it could be taken into account when considering the dose and type of anti-TNF in IBD patients.

show abstract

Section: Methodsmentioning

confidence: 99%

A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF

Romero-Cara¹,

Torres-Moreno²,

Pedregosa³

et al. 2018

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…FCGR3A, which resides in Kupffer cells (KCs), can contribute to the inhibition of the growth of liver tumor cells [17]. More interestingly, FCGR3A gene polymorphism was associated with an increased risk of lowgrade precursor lesions of cervical carcinoma [18]. FCGR3A gene polymorphism was positively associated with increased genetic risk of colorectal carcinoma [19].…”

Section: Introductionmentioning

confidence: 99%

FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma

Sun

Fei

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Low-grade gliomas (LGGs) are primary invasive brain tumors that grow slowly but are incurable and eventually develop into high malignant glioma. Fc fragment of IgG receptor IIIa (FCGR3A) gene polymorphism may correlate with some cancers’ treatment responses. However, the expression and prognosis value of FCGR3A and correlation with tumor-immune infiltrate in LGG remain unclear. FCGR3A mRNA expression in gastric cancer (GC) was examined using TIMER and GEPIA databases. Correlations between FCGR3A expression and clinicopathological parameters were analyzed using ULACAN and CGGA databases. GEPIA, OncoLnc, and ULACAN databases were used to examine the clinical prognostic significance of FCGR3A in LGG. TIMER was used to analyze the correlations among FCGR3A and tumor-infiltrating immune cells. Signaling pathways related to FCGR3A expression were identified by LinkedOmics. We found that FCGR3A expression was higher in LGG than in normal tissue and was correlated with various clinical parameters. In addition, high FCGR3A expression predicted poor overall survival in LGG. More importantly, FCGR3A expression positively correlated with immune checkpoint molecules, including PD1, PD-L1, PD-L2, CTLA4, LAG-3 and TIM-3, and tumor-associated macrophage (TAM) gene markers in LGG. GO and KEGG pathway analyses indicated that TUBA1C may potentially regulate the pathogenesis of LGG through immune-related pathways. These findings indicated that FCGR3A plays a vital role in the infiltration of immune cells and could constitute a promising prognostic biomarker in LGG patients.

show abstract

“…Additionally, the role of Fc gamma receptors (FcγR) polymorphisms (FCGR3A V158F) in cancer susceptibility and viral infections has been reported in several studies (Poonia et al, 2010;Conesa et al, 2010). Fc gamma receptors (FcγR) a member of immunoglobulin superfamily is essential participant in many immune system functions.…”

Section: Introductionmentioning

confidence: 99%

“…Results of this study indicate that individuals with the V158 allele of FCGR3A were susceptible to a higher risk of HIV infection (Poonia et al, 2010). To further explore the effect of rs396991 on human diseases and viral infections, Conesa et al demonstrated that this SNP is associated with the HPV persistent infection and an elevated risk of pre-cancerous lesions of the uterine cervix (Conesa et al, 2010). However, the potential association of ABCB1 and FCGR3A gene polymorphisms with cervical cancer is required to be extensively studied.…”

Section: Introductionmentioning

confidence: 99%

Association of a genetic variant in the ATP-binding cassette sub-family B member 1 with risk of cervical cancer

Armanpour¹,

Malekzade²,

Maftooh³

et al. 2022

Human Gene

View full text Add to dashboard Cite

Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma

Cited by 9 publications

References 34 publications

A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF

A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF

FCGR3A Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lower-Grade Glioma

Association of a genetic variant in the ATP-binding cassette sub-family B member 1 with risk of cervical cancer

Contact Info

Product

Resources

About